Author:
Propper David,Jones Keith,Anthoney D. Alan,Mansoor Wasat,Ford Daniel,Eatock Martin,Agarwal Roshan,Inatani Michiyasu,Saito Tomohisa,Abe Masaichi,Evans T. R. Jeffry
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference21 articles.
1. Beretta GL, Perego P, Zunino F. Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert Opin Ther Targets. 2008;12:1243–56.
2. FDA. United States Food and Drug Administration: Camptosar label. 2005. cited; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020571s024,027,028lbl.pdf .
3. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 1995;6:129–32.
4. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004;22:4319–28.
5. Langer CJ. The global role of irinotecan in the treatment of lung cancer: 2003 update. Oncology (Williston Park). 2003;17:30–40.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献